• Quick 30-90 Day Registration in Macau
• 100% Registration Success Rate
• No Additional Clinical Trials
• Zero Additional Investments
• 40 New Drugs Registered Last Year Alone

Expanding Access, Enhancing Capabilities

• Broad Distribution Network: After registration, all drugs become eligible for distribution across 44 major hospitals in the Guangdong Great Bay Area, Hainan, and Tianjin, serving over 120 million people.
• Reaching Far and Wide: Our extensive network ensures medications are swiftly available to a vast patient base, opening access to an additional 1.2 billion people in Northern China. Patients can travel to these hospitals for critical treatments.

Critical Care Solutions

• Pediatric and Clinically Urgent Medications: Pediatric orphan drugs and clinically urgent medications are now accessible directly to top hospitals in Beijing, including the top ten pediatric hospitals nationwide, as well as hospitals in Shanghai, Tianjin, and Chongqing. These drugs, classified as clinically urgent and irreplaceable, benefit from a streamlined approval process after Macau registration, allowing entry to these leading hospitals without the need for national registration and clinical trials.
• Fast-Track National Approval: For clinically urgent, irreplaceable innovative drugs, our strategy allows us to achieve national approval within three to six months without clinical trials by collecting limited real-world clinical data from the initial launch after Macau registration in hospitals across the Greater Bay Area and major hospitals in Beijing. This process ensures that patients in need receive critical treatments in a timely manner.
• Media Coverage for Broader Awareness: Extensive media coverage ensures patients across the country who can afford out-of-pocket treatments are informed and can receive timely medical assistance.

Accelerate access to treatment with Fast Track Registration in Macau for drugs addressing unmet medical needs. Our streamlined process allows manufacturers of innovative and clinically urgent drugs to swiftly enter the Chinese market, facilitating rapid recovery of their development investments.